Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Lung Cancer | Review

Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature

Authors: Debbie Cavers, Mia Nelson, Jasmin Rostron, Kathryn A. Robb, Lynsey R. Brown, Christine Campbell, Ahsan R. Akram, Graeme Dickie, Melanie Mackean, Edwin J. R. van Beek, Frank Sullivan, Robert J. Steele, Aileen R. Neilson, David Weller

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Targeted lung cancer screening is effective in reducing mortality by upwards of twenty percent. However, screening is not universally available and uptake is variable and socially patterned. Understanding screening behaviour is integral to designing a service that serves its population and promotes equitable uptake. We sought to review the literature to identify barriers and facilitators to screening to inform the development of a pilot lung screening study in Scotland.

Methods

We used Arksey and O’Malley’s scoping review methodology and PRISMA-ScR framework to identify relevant literature to meet the study aims. Qualitative, quantitative and mixed methods primary studies published between January 2000 and May 2021 were identified and reviewed by two reviewers for inclusion, using a list of search terms developed by the study team and adapted for chosen databases.

Results

Twenty-one articles met the final inclusion criteria. Articles were published between 2003 and 2021 and came from high income countries. Following data extraction and synthesis, findings were organised into four categories: Awareness of lung screening, Enthusiasm for lung screening, Barriers to lung screening, and Facilitators or ways of promoting uptake of lung screening. Awareness of lung screening was low while enthusiasm was high. Barriers to screening included fear of a cancer diagnosis, low perceived risk of lung cancer as well as practical barriers of cost, travel and time off work. Being health conscious, provider endorsement and seeking reassurance were all identified as facilitators of screening participation.

Conclusions

Understanding patient reported barriers and facilitators to lung screening can help inform the implementation of future lung screening pilots and national lung screening programmes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.CrossRef Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.CrossRef
2.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Am Cancer Soc. 2021;71(3):209–49. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Am Cancer Soc. 2021;71(3):209–49.
4.
go back to reference Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.CrossRef Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.CrossRef
5.
go back to reference Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–31.CrossRef Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–31.CrossRef
6.
go back to reference Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.CrossRef Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.CrossRef
7.
go back to reference Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135–51.CrossRef Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135–51.CrossRef
8.
go back to reference Barrett J, Hamilton W. Pathways to the diagnosis of lung cancer in the UK: a cohort study. BMC Fam Pract. 2008;9(1):31.CrossRef Barrett J, Hamilton W. Pathways to the diagnosis of lung cancer in the UK: a cohort study. BMC Fam Pract. 2008;9(1):31.CrossRef
9.
go back to reference Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M. Is late diagnosis of lung cancer inevitable? Interview study of patients’ recollections of symptoms before diagnosis. Thorax. 2005;60(4):314–9.CrossRef Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M. Is late diagnosis of lung cancer inevitable? Interview study of patients’ recollections of symptoms before diagnosis. Thorax. 2005;60(4):314–9.CrossRef
10.
go back to reference Birt L, Hall N, Emery J, Banks J, Mills K, Johnson M, et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir Res. 2014;1(1): e000067.CrossRef Birt L, Hall N, Emery J, Banks J, Mills K, Johnson M, et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir Res. 2014;1(1): e000067.CrossRef
11.
go back to reference Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–65.CrossRef Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–65.CrossRef
12.
go back to reference Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29.CrossRef Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29.CrossRef
13.
go back to reference Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (London, England). 1999;354(9173):99–105.CrossRef Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (London, England). 1999;354(9173):99–105.CrossRef
14.
go back to reference Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002;222(3):773–81.CrossRef Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002;222(3):773–81.CrossRef
15.
go back to reference Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. The Lancet. 2003;362(9384):593–7.CrossRef Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. The Lancet. 2003;362(9384):593–7.CrossRef
16.
go back to reference Walter JE, Heuvelmans MA, Bock GHD, Yousaf-Khan U, Groen HJM, Aalst CMVD, et al. Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. Thorax. 2018;73(8):741–7.CrossRef Walter JE, Heuvelmans MA, Bock GHD, Yousaf-Khan U, Groen HJM, Aalst CMVD, et al. Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. Thorax. 2018;73(8):741–7.CrossRef
17.
go back to reference Ostrowski M, Marjański T. Low-dose computed tomography screening reduces lung cancer mortality. Adv Med Sci. 2018;63:230–6.CrossRef Ostrowski M, Marjański T. Low-dose computed tomography screening reduces lung cancer mortality. Adv Med Sci. 2018;63:230–6.CrossRef
18.
go back to reference Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, et al. Lung Screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med. 2020;201(8):965–75.CrossRef Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, et al. Lung Screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med. 2020;201(8):965–75.CrossRef
19.
go back to reference Marcus PM, Lenz S, Sammons D, Black W, Garg K. Recruitment methods employed in the National Lung Screening Trial. J Med Screen. 2012;19(2):94–102.CrossRef Marcus PM, Lenz S, Sammons D, Black W, Garg K. Recruitment methods employed in the National Lung Screening Trial. J Med Screen. 2012;19(2):94–102.CrossRef
20.
go back to reference McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362–71.CrossRef McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362–71.CrossRef
21.
go back to reference Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
22.
go back to reference Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, The National Lung Screening Trial Research Team Writing committee, et al. Baseline characteristics of participants in the randomized national lung screening trial. JNCI. 2010;102(23):1771–9.CrossRef Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, The National Lung Screening Trial Research Team Writing committee, et al. Baseline characteristics of participants in the randomized national lung screening trial. JNCI. 2010;102(23):1771–9.CrossRef
23.
go back to reference Hestbech MS, Siersma V, Dirksen A, Pedersen JH, Brodersen J. Participation bias in a randomised trial of screening for lung cancer. Lung Cancer. 2011;73(3):325–31.CrossRef Hestbech MS, Siersma V, Dirksen A, Pedersen JH, Brodersen J. Participation bias in a randomised trial of screening for lung cancer. Lung Cancer. 2011;73(3):325–31.CrossRef
24.
go back to reference Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON lung cancer screening study. J Thorac Oncol. 2015;10(5):747–53.CrossRef Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON lung cancer screening study. J Thorac Oncol. 2015;10(5):747–53.CrossRef
25.
go back to reference Zahnd WE, Eberth JM. Lung cancer screening utilization: a behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57(2):250–5.CrossRef Zahnd WE, Eberth JM. Lung cancer screening utilization: a behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57(2):250–5.CrossRef
27.
go back to reference Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef
28.
go back to reference Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13:48.CrossRef Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13:48.CrossRef
29.
go back to reference Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation science : IS. 2010;5:69.CrossRef Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation science : IS. 2010;5:69.CrossRef
30.
go back to reference Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13:224.CrossRef Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13:224.CrossRef
31.
go back to reference Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.CrossRef Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.CrossRef
32.
go back to reference Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:59.CrossRef Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:59.CrossRef
33.
go back to reference Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8(1):45.CrossRef Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8(1):45.CrossRef
34.
go back to reference Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol. 2006;6(1):35.CrossRef Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol. 2006;6(1):35.CrossRef
35.
go back to reference Cavers D, Cunningham-Burley S, Watson E, Banks E, Campbell C. Experience of living with cancer and comorbid illness: protocol for a qualitative systematic review. BMJ Open. 2017;7(5): e013383.CrossRef Cavers D, Cunningham-Burley S, Watson E, Banks E, Campbell C. Experience of living with cancer and comorbid illness: protocol for a qualitative systematic review. BMJ Open. 2017;7(5): e013383.CrossRef
36.
go back to reference Cavers D, Habets L, Cunningham-Burley S, Watson E, Banks E, Campbell C. Living with and beyond cancer with comorbid illness: a qualitative systematic review and evidence synthesis. J Cancer Surviv. 2019;13(1):148–59.CrossRef Cavers D, Habets L, Cunningham-Burley S, Watson E, Banks E, Campbell C. Living with and beyond cancer with comorbid illness: a qualitative systematic review and evidence synthesis. J Cancer Surviv. 2019;13(1):148–59.CrossRef
37.
go back to reference Ali N, Lifford KJ, Carter B, McRonald F, Yadegarfar G, Baldwin DR, et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015;5(7): e008254.CrossRef Ali N, Lifford KJ, Carter B, McRonald F, Yadegarfar G, Baldwin DR, et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015;5(7): e008254.CrossRef
38.
go back to reference Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM. A qualitative study exploring why individuals opt out of lung cancer screening. Fam Pract. 2017;34(2):239–44. Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM. A qualitative study exploring why individuals opt out of lung cancer screening. Fam Pract. 2017;34(2):239–44.
39.
go back to reference Carter-Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what do long-term smokers know and believe? Health Expect. 2017;20(1):59–68.CrossRef Carter-Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what do long-term smokers know and believe? Health Expect. 2017;20(1):59–68.CrossRef
40.
go back to reference Delmerico J, Hyland A, Celestino P, Reid M, Cummings KM. Patient willingness and barriers to receiving a CT scan for lung cancer screening. Lung Cancer. 2014;84(3):307–9.CrossRef Delmerico J, Hyland A, Celestino P, Reid M, Cummings KM. Patient willingness and barriers to receiving a CT scan for lung cancer screening. Lung Cancer. 2014;84(3):307–9.CrossRef
41.
go back to reference Draucker CB, Rawl SM, Vode E, Carter-Harris L. Understanding the decision to screen for lung cancer or not: a qualitative analysis. Health Expect. 2019;22(6):1314–21.CrossRef Draucker CB, Rawl SM, Vode E, Carter-Harris L. Understanding the decision to screen for lung cancer or not: a qualitative analysis. Health Expect. 2019;22(6):1314–21.CrossRef
42.
go back to reference Greene PA, Sayre G, Heffner JL, Klein DE, Krebs P, Au DH, et al. Challenges to educating smokers about lung cancer screening: a qualitative study of decision making experiences in primary care. J Cancer Educ. 2019;34(6):1142–9.CrossRef Greene PA, Sayre G, Heffner JL, Klein DE, Krebs P, Au DH, et al. Challenges to educating smokers about lung cancer screening: a qualitative study of decision making experiences in primary care. J Cancer Educ. 2019;34(6):1142–9.CrossRef
43.
go back to reference Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526–31.CrossRef Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526–31.CrossRef
44.
go back to reference Lowenstein M, Vijayaraghavan M, Burke NJ, Karliner L, Wang S, Peters M, et al. Real-world lung cancer screening decision-making: barriers and facilitators. Lung Cancer. 2019;133:32–7.CrossRef Lowenstein M, Vijayaraghavan M, Burke NJ, Karliner L, Wang S, Peters M, et al. Real-world lung cancer screening decision-making: barriers and facilitators. Lung Cancer. 2019;133:32–7.CrossRef
45.
go back to reference Percac-Lima S, Ashburner JM, Atlas SJ, Rigotti NA, Flores EJ, Kuchukhidze S, et al. Barriers to and interest in lung cancer screening among Latino and Non-Latino current and former smokers. J Immigr Minor Health. 2019;21(6):1313–24.CrossRef Percac-Lima S, Ashburner JM, Atlas SJ, Rigotti NA, Flores EJ, Kuchukhidze S, et al. Barriers to and interest in lung cancer screening among Latino and Non-Latino current and former smokers. J Immigr Minor Health. 2019;21(6):1313–24.CrossRef
46.
go back to reference Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expect. 2017;20(4):563–73.CrossRef Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expect. 2017;20(4):563–73.CrossRef
47.
go back to reference Quaife SL, Vrinten C, Ruparel M, Janes SM, Beeken RJ, Waller J, et al. Smokers’ interest in a lung cancer screening programme: a national survey in England. BMC Cancer. 2018;18(1):1–10.CrossRef Quaife SL, Vrinten C, Ruparel M, Janes SM, Beeken RJ, Waller J, et al. Smokers’ interest in a lung cancer screening programme: a national survey in England. BMC Cancer. 2018;18(1):1–10.CrossRef
48.
go back to reference Raju S, Khawaja A, Han X, Wang X, Mazzone PJ. Lung cancer screening: characteristics of nonparticipants and potential screening barriers. Clin Lung Cancer. 2020;21(5):e329–36.CrossRef Raju S, Khawaja A, Han X, Wang X, Mazzone PJ. Lung cancer screening: characteristics of nonparticipants and potential screening barriers. Clin Lung Cancer. 2020;21(5):e329–36.CrossRef
49.
go back to reference Raz DJ, Wu G, Nelson RA, Sun V, Wu S, Alem A, et al. Perceptions and utilization of lung cancer screening among smokers enrolled in a tobacco cessation program. Clin Lung Cancer. 2019;20(1):e115–22.CrossRef Raz DJ, Wu G, Nelson RA, Sun V, Wu S, Alem A, et al. Perceptions and utilization of lung cancer screening among smokers enrolled in a tobacco cessation program. Clin Lung Cancer. 2019;20(1):e115–22.CrossRef
50.
go back to reference Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. PLoS ONE [Electronic Resource]. 2018;13(7): e0196758.CrossRef Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. PLoS ONE [Electronic Resource]. 2018;13(7): e0196758.CrossRef
51.
go back to reference Schiffelbein JE, Carluzzo KL, Hasson RM, Alford-Teaster JA, Imset I, Onega T. Barriers, facilitators, and suggested interventions for lung cancer screening among a rural screening-eligible population. J Prim Care Community Health. 2020;11:2150132720930544.CrossRef Schiffelbein JE, Carluzzo KL, Hasson RM, Alford-Teaster JA, Imset I, Onega T. Barriers, facilitators, and suggested interventions for lung cancer screening among a rural screening-eligible population. J Prim Care Community Health. 2020;11:2150132720930544.CrossRef
52.
go back to reference Schnoll RA, Bradley P, Miller SM, Unger M, Babb J, Cornfeld M. Psychological issues related to the use of spiral CT for lung cancer early detection. Lung Cancer. 2003;39(3):315–25.CrossRef Schnoll RA, Bradley P, Miller SM, Unger M, Babb J, Cornfeld M. Psychological issues related to the use of spiral CT for lung cancer early detection. Lung Cancer. 2003;39(3):315–25.CrossRef
54.
go back to reference Smits SE, McCutchan GM, Hanson JA, Brain KE. Attitudes towards lung cancer screening in a population sample. Health Expect. 2018;21(6):1150–8.CrossRef Smits SE, McCutchan GM, Hanson JA, Brain KE. Attitudes towards lung cancer screening in a population sample. Health Expect. 2018;21(6):1150–8.CrossRef
55.
go back to reference Stephens SE, Foley KL, Miller D, Bellinger CR. The effects of health disparities on perceptions about lung cancer screening (LCS): survey results of a patient sample. Lung. 2019;197(6):735–40.CrossRef Stephens SE, Foley KL, Miller D, Bellinger CR. The effects of health disparities on perceptions about lung cancer screening (LCS): survey results of a patient sample. Lung. 2019;197(6):735–40.CrossRef
56.
go back to reference Tonge JE, Atack M, Crosbie PA, Barber PV, Booton R, Colligan D. “To know or not to know…?” Push and pull in ever smokers lung screening uptake decision-making intentions. Health Expect. 2019;22(2):162–72.CrossRef Tonge JE, Atack M, Crosbie PA, Barber PV, Booton R, Colligan D. “To know or not to know…?” Push and pull in ever smokers lung screening uptake decision-making intentions. Health Expect. 2019;22(2):162–72.CrossRef
57.
go back to reference Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer. 2017;106:42–9.CrossRef Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer. 2017;106:42–9.CrossRef
58.
go back to reference Leventhal H, Kelly K, Leventhal EA. Population risk, actual risk, perceived risk, and cancer control: a discussion. J Natl Cancer Inst Monogr. 1999;25:81–5.CrossRef Leventhal H, Kelly K, Leventhal EA. Population risk, actual risk, perceived risk, and cancer control: a discussion. J Natl Cancer Inst Monogr. 1999;25:81–5.CrossRef
59.
go back to reference Cavers D, Calanzani N, Orbell S, Vojt G, Steele RJC, Brownlee L, et al. Development of an evidence-based brief ‘talking’ intervention for non-responders to bowel screening for use in primary care: stakeholder interviews. BMC Fam Pract. 2018;19(1):105.CrossRef Cavers D, Calanzani N, Orbell S, Vojt G, Steele RJC, Brownlee L, et al. Development of an evidence-based brief ‘talking’ intervention for non-responders to bowel screening for use in primary care: stakeholder interviews. BMC Fam Pract. 2018;19(1):105.CrossRef
60.
go back to reference Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346: f158.CrossRef Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346: f158.CrossRef
61.
go back to reference Henriksen MJV, Guassora AD, Brodersen J. Preconceptions influence women’s perceptions of information on breast cancer screening: a qualitative study. BMC Res Notes. 2015;8(1):404.CrossRef Henriksen MJV, Guassora AD, Brodersen J. Preconceptions influence women’s perceptions of information on breast cancer screening: a qualitative study. BMC Res Notes. 2015;8(1):404.CrossRef
62.
go back to reference von Wagner C, Good A, Whitaker KL, Wardle J. Psychosocial determinants of socioeconomic inequalities in cancer screening participation: a conceptual framework. Epidemiol Rev. 2011;33:135–47.CrossRef von Wagner C, Good A, Whitaker KL, Wardle J. Psychosocial determinants of socioeconomic inequalities in cancer screening participation: a conceptual framework. Epidemiol Rev. 2011;33:135–47.CrossRef
63.
go back to reference Feldstein AC, Perrin N, Rosales AG, Schneider J, Rix MM, Glasgow RE. Patient barriers to mammography identified during a reminder program. J Womens Health (Larchmt). 2011;20(3):421–8.CrossRef Feldstein AC, Perrin N, Rosales AG, Schneider J, Rix MM, Glasgow RE. Patient barriers to mammography identified during a reminder program. J Womens Health (Larchmt). 2011;20(3):421–8.CrossRef
64.
go back to reference Reynolds LM, Bissett IP, Consedine NS. Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust. BMC Cancer. 2018;18(1):518.CrossRef Reynolds LM, Bissett IP, Consedine NS. Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust. BMC Cancer. 2018;18(1):518.CrossRef
65.
go back to reference Beeken RJ, Simon AE, von Wagner C, Whitaker KL, Wardle J. Cancer fatalism: deterring early presentation and increasing social inequalities? Cancer Epidemiol Biomark Prev. 2011;20(10):2127–31.CrossRef Beeken RJ, Simon AE, von Wagner C, Whitaker KL, Wardle J. Cancer fatalism: deterring early presentation and increasing social inequalities? Cancer Epidemiol Biomark Prev. 2011;20(10):2127–31.CrossRef
66.
go back to reference Miles A, Rainbow S, von Wagner C. Cancer fatalism and poor self-rated health mediate the association between socioeconomic status and uptake of colorectal cancer screening in England. Cancer Epidemiol Biomark Prev. 2011;20(10):2132–40.CrossRef Miles A, Rainbow S, von Wagner C. Cancer fatalism and poor self-rated health mediate the association between socioeconomic status and uptake of colorectal cancer screening in England. Cancer Epidemiol Biomark Prev. 2011;20(10):2132–40.CrossRef
67.
go back to reference Davis JL, Bynum SA, Katz RV, Buchanan K, Green BL. Sociodemographic differences in fears and mistrust contributing to unwillingness to participate in cancer screenings. J Health Care Poor Underserved. 2012;23(4 Suppl):67–76.CrossRef Davis JL, Bynum SA, Katz RV, Buchanan K, Green BL. Sociodemographic differences in fears and mistrust contributing to unwillingness to participate in cancer screenings. J Health Care Poor Underserved. 2012;23(4 Suppl):67–76.CrossRef
68.
70.
go back to reference Doblytė S. The vicious cycle of distrust: access, quality, and efficiency within a post-communist mental health system. Soc Sci Med. 2022;292: 114573.CrossRef Doblytė S. The vicious cycle of distrust: access, quality, and efficiency within a post-communist mental health system. Soc Sci Med. 2022;292: 114573.CrossRef
71.
go back to reference Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.CrossRef Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.CrossRef
73.
go back to reference Wardle J, Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health. 2003;57(6):440–3.CrossRef Wardle J, Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health. 2003;57(6):440–3.CrossRef
74.
go back to reference Kaushal A, Hirst Y, Tookey S, Kerrison RS, Marshall S, Prentice A, et al. Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population. Prev Med. 2020;141: 106268.CrossRef Kaushal A, Hirst Y, Tookey S, Kerrison RS, Marshall S, Prentice A, et al. Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population. Prev Med. 2020;141: 106268.CrossRef
75.
go back to reference Hope KA, Moss E, Redman CWE, Sherman SM. Psycho-social influences upon older women’s decision to attend cervical screening: a review of current evidence. Prev Med. 2017;101:60–6.CrossRef Hope KA, Moss E, Redman CWE, Sherman SM. Psycho-social influences upon older women’s decision to attend cervical screening: a review of current evidence. Prev Med. 2017;101:60–6.CrossRef
76.
go back to reference Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect. 2002;5(2):104–13.CrossRef Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect. 2002;5(2):104–13.CrossRef
77.
go back to reference Renzi C, Whitaker KL, Wardle J. Over-reassurance and undersupport after a ‘false alarm’: a systematic review of the impact on subsequent cancer symptom attribution and help seeking. BMJ Open. 2015;5(2): e007002.CrossRef Renzi C, Whitaker KL, Wardle J. Over-reassurance and undersupport after a ‘false alarm’: a systematic review of the impact on subsequent cancer symptom attribution and help seeking. BMJ Open. 2015;5(2): e007002.CrossRef
78.
go back to reference Barnett KN, Weller D, Smith S, Orbell S, Vedsted P, Steele RJC, et al. Understanding of a negative bowel screening result and potential impact on future symptom appraisal and help-seeking behaviour: a focus group study. Health Expect. 2017;20(4):584–92.CrossRef Barnett KN, Weller D, Smith S, Orbell S, Vedsted P, Steele RJC, et al. Understanding of a negative bowel screening result and potential impact on future symptom appraisal and help-seeking behaviour: a focus group study. Health Expect. 2017;20(4):584–92.CrossRef
79.
go back to reference Brain K, Carter B, Lifford KJ, Burke O, Devaraj A, Baldwin DR, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Lung Cancer. 2017;72(10):912–8. Brain K, Carter B, Lifford KJ, Burke O, Devaraj A, Baldwin DR, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Lung Cancer. 2017;72(10):912–8.
80.
go back to reference Steliga MA, Yang P. Integration of smoking cessation and lung cancer screening. Transl Lung Cancer Res. 2019;8(Suppl 1):S88-s94.CrossRef Steliga MA, Yang P. Integration of smoking cessation and lung cancer screening. Transl Lung Cancer Res. 2019;8(Suppl 1):S88-s94.CrossRef
81.
go back to reference Shelton RC, Lee M. Sustaining evidence-based interventions and policies: recent innovations and future directions in implementation science. Am J Public Health. 2019;109(S2):S132–4.CrossRef Shelton RC, Lee M. Sustaining evidence-based interventions and policies: recent innovations and future directions in implementation science. Am J Public Health. 2019;109(S2):S132–4.CrossRef
Metadata
Title
Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature
Authors
Debbie Cavers
Mia Nelson
Jasmin Rostron
Kathryn A. Robb
Lynsey R. Brown
Christine Campbell
Ahsan R. Akram
Graeme Dickie
Melanie Mackean
Edwin J. R. van Beek
Frank Sullivan
Robert J. Steele
Aileen R. Neilson
David Weller
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02255-8

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine